OBJECTIVES: To determine the effectiveness of enzyme replacement therapy (ERT) for adults with late-onset Pompe disease. DESIGN: A longitudinal cohort study including prospective and retrospective clinical outcome data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data. PARTICIPANTS: Consenting adults (N = 62) with a diagnosis of late-onset Pompe disease who attended a specialist treatment centre in England. This cohort represented 83 % of all patients in the UK with a confirmed diagnosis of this rare condition. At study entry, all but three patients were receiving ERT (range of treatment duration, 0 to 3.1 years). OUTCOME MEASURES: Percent predicted forced vital capacity (%FVC); ventilation dependency; mobility; 6 min walk test (6MWT); muscle strength and body mass index (BMI). RESULTS: An association was found between time on ERT and significant increases in the distance walked in the 6MWT (p < 0.001) and muscle strength scores (p < 0.001). Improvements in both these measures were seen over the first 2 years of treatment with ERT. No statistically significant relationship was found between time on ERT and respiratory function or in BMI. CONCLUSIONS: These data provide some further evidence of the effectiveness of ERT in adults with late-onset Pompe disease. SYNOPSIS: The results of this longitudinal cohort study of 62 adults with late-onset Pompe disease, provide further evidence on the effectiveness of ERT in this rare condition.
OBJECTIVES: To determine the effectiveness of enzyme replacement therapy (ERT) for adults with late-onset Pompe disease. DESIGN: A longitudinal cohort study including prospective and retrospective clinical outcome data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data. PARTICIPANTS: Consenting adults (N = 62) with a diagnosis of late-onset Pompe disease who attended a specialist treatment centre in England. This cohort represented 83 % of all patients in the UK with a confirmed diagnosis of this rare condition. At study entry, all but three patients were receiving ERT (range of treatment duration, 0 to 3.1 years). OUTCOME MEASURES: Percent predicted forced vital capacity (%FVC); ventilation dependency; mobility; 6 min walk test (6MWT); muscle strength and body mass index (BMI). RESULTS: An association was found between time on ERT and significant increases in the distance walked in the 6MWT (p < 0.001) and muscle strength scores (p < 0.001). Improvements in both these measures were seen over the first 2 years of treatment with ERT. No statistically significant relationship was found between time on ERT and respiratory function or in BMI. CONCLUSIONS: These data provide some further evidence of the effectiveness of ERT in adults with late-onset Pompe disease. SYNOPSIS: The results of this longitudinal cohort study of 62 adults with late-onset Pompe disease, provide further evidence on the effectiveness of ERT in this rare condition.
Authors: N A M E Van der Beek; M L C Hagemans; A J J Reuser; W C J Hop; A T Van der Ploeg; P A Van Doorn; J H J Wokke Journal: Neuromuscul Disord Date: 2008-12-11 Impact factor: 4.296
Authors: H Van den Hout; A J Reuser; A G Vulto; M C Loonen; A Cromme-Dijkhuis; A T Van der Ploeg Journal: Lancet Date: 2000-07-29 Impact factor: 79.321
Authors: C Angelini; C Semplicini; S Ravaglia; B Bembi; S Servidei; E Pegoraro; M Moggio; M Filosto; E Sette; G Crescimanno; P Tonin; R Parini; L Morandi; G Marrosu; G Greco; O Musumeci; G Di Iorio; G Siciliano; M A Donati; F Carubbi; M Ermani; T Mongini; A Toscano Journal: J Neurol Date: 2011-11-12 Impact factor: 4.849
Authors: P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith Journal: Neurology Date: 2006-12-06 Impact factor: 9.910
Authors: Hannerieke M P van den Hout; Wim Hop; Otto P van Diggelen; Jan A M Smeitink; G Peter A Smit; Bwee-Tien T Poll-The; Henk D Bakker; M Christa B Loonen; Johannis B C de Klerk; Arnold J J Reuser; Ans T van der Ploeg Journal: Pediatrics Date: 2003-08 Impact factor: 7.124
Authors: K Wyatt; W Henley; L Anderson; R Anderson; V Nikolaou; K Stein; L Klinger; D Hughes; S Waldek; R Lachmann; A Mehta; A Vellodi; S Logan Journal: Health Technol Assess Date: 2012 Impact factor: 4.014
Authors: Federica Montagnese; E Barca; O Musumeci; S Mondello; A Migliorato; A Ciranni; C Rodolico; P De Filippi; C Danesino; A Toscano Journal: J Neurol Date: 2015-02-12 Impact factor: 4.849
Authors: Miao Xu; Omid Motabar; Marc Ferrer; Juan J Marugan; Wei Zheng; Elizabeth A Ottinger Journal: Ann N Y Acad Sci Date: 2016-05-04 Impact factor: 5.691
Authors: Benedikt Schoser; Andrew Stewart; Steve Kanters; Alaa Hamed; Jeroen Jansen; Keith Chan; Mohammad Karamouzian; Antonio Toscano Journal: J Neurol Date: 2016-07-02 Impact factor: 4.849
Authors: André Lollert; Clemens Stihl; Andreas M Hötker; Eugen Mengel; Jochem König; Katharina Laudemann; Seyfullah Gökce; Christoph Düber; Gundula Staatz Journal: PLoS One Date: 2018-01-09 Impact factor: 3.240
Authors: Erik van der Wal; Atze J Bergsma; Tom J M van Gestel; Stijn L M In 't Groen; Holm Zaehres; Marcos J Araúzo-Bravo; Hans R Schöler; Ans T van der Ploeg; W W M Pim Pijnappel Journal: Mol Ther Nucleic Acids Date: 2017-03-14
Authors: Jan C van der Meijden; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Nadine A M E van der Beek; Ans T van der Ploeg Journal: Orphanet J Rare Dis Date: 2018-05-22 Impact factor: 4.123
Authors: Meng Yuan; Eleni-Rosalina Andrinopoulou; Michelle E Kruijshaar; Aglina Lika; Laurike Harlaar; Ans T van der Ploeg; Dimitris Rizopoulos; Nadine A M E van der Beek Journal: Orphanet J Rare Dis Date: 2020-09-03 Impact factor: 4.123